Healthcare

May 22, 2019

1

ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries

Remote monitoring and patient self-monitoring can drive CPAP adherence for people with sleep apnea, according to research presented by ResMed (NYSE: RMD) (ASX: RMD) at the American Thoracic Society’s 2019 ATS International Conference.

Average adherence to PAP (positive airway pressure), the gold standard for treating sleep apnea, is approximately 50 percent when using legacy technology with no cloud connectivity or remote monitoring capabilities."...

Continue Reading >

May 21, 2019

2

New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery

(AETOS Wire) -- Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enrolled 69 adult patients scheduled for......

Continue Reading >

May 20, 2019

3

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1

  • Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
  • Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3
  • FDA grants priority review to application for regulatory approval for nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD)
  • ...

    Continue Reading >

May 20, 2019

4

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought

(AETOS Wire) -- ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference.

The study found significant differences in one-year adherence between people of different ages and disease severity levels:

May 20, 2019

5

Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses

(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam. “We look forward to presenting data at ASCO and EHA that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “These data demonstrate our continued commitment to the discovery, development and delivery of medicines for patients with cancers.” At ASCO, Takeda will present data from both its lung portfolio and hematology portfolio. Results from a Phase 1/2 first-in-human, open-label, multicenter......

Continue Reading >

May 20, 2019

6

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®

(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019......

Continue Reading >

May 18, 2019

7

Takeda and London School of Hygiene & Tropical Medicine Establish ''Takeda Chair in Global Child Health''

(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in Global Child Health, endowed by a £3 million donation by Takeda to LSHTM. The School’s first fully endowed corporate chair, it will support vital research into reducing 5.3 million child deaths in low and middle-income countries. Takeda’s donation will enable LSHTM to recruit a world-class researcher and educator to join its innovative academic team as the first holder of the Takeda Chair in Global Child Health. This post will play a critical role in consolidating LSHTM’s child health research across more than 100 countries, accelerating change for one of the biggest......

Continue Reading >

May 18, 2019

8

German Diabetes Clinic Increases Diabetic Retinopathy Screenings From Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System

(AETOS Wire) -- Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1 The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s......

Continue Reading >

May 15, 2019

9

LifeArc and GVK BIO Celebrate a Decade of Partnership, Transforming Research into Life-Saving Medicines

(AETOS Wire)-- GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, are pleased to announce the 10th anniversary of a successful partnership. The collaboration between LifeArc and GVK BIO brings together two organizations with a singular vision: advancing novel research ideas into potential medicines that can make a significant difference to patients.

LifeArc’s"...

Continue Reading >

May 15, 2019

10

Q3 Medical Devices Limited Enters into a Distribution Agreement with Medtronic for its Biodegradable Biliary and Pancreatic Stent

(AETOS Wire)-- Q3 Medical Devices Limited (“Q3 Medical”) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biodegradable biliary and pancreatic stent designed as an alternative to traditional plastic stents.

Medtronic’s Gastrointestinal and Hepatology business, which is part of the Minimally"...

Continue Reading >


Forex News Headline



Forex Market Video